Drug Detail

Information about Opdivo + Yervoy

Generic Name	Nivolumab + Ipilimumab
IND
Brand Name (US)	Opdivo + Yervoy
Manufacturer	Bristol-Myers Squibb
Drug Type	Anti-PD-1 antibody, Anti-CTLA-4 antibody
Delivery	Intravenous
Approval Status	Approved for a non-GIST application
Indications
Overall Strategy	Immune system
Strategy	Immunotherapy
Drug Category	PD-1 inhibitor + CTLA-4 inhibitor

Links
Trials of this drug
	Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic or Unresectable Sarcoma

	Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery

Trial results
	Jour of Immunotherpy of Cancer 9/28/2024 "A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analyses

	Study Results - NCT02500797